Zinger Key Points
- Microbot shares are trading higher Monday after the company received FDA approval to proceed with its human clinical trial.
- Microbot says the study will be conducted in the U.S., and it has already signed a clinical trial service agreement with an academic center.
- Discover Fast-Growing Stocks Every Month
Microbot Medical Inc. MBOT shares are trading higher Monday after the company announced that it has received FDA approval to proceed with its human clinical trial as part of its Investigational Device Exemption (IDE) application for its LIBERTY Endovascular Robotic Surgical System.
The Details:
Microbot said the study will be conducted in the U.S., and it has already signed a clinical trial service agreement with a leading academic medical center. In parallel to commencing the pivotal human clinical trial, the company is completing its biocompatibility tests as required by its IDE application.
"The recent authorization by the FDA to commence our pivotal clinical study, following submission of the results of our extensive pre-clinical studies and tests, reinforces our confidence in our innovative technology,” commented Harel Gadot, CEO of Microbot Medical.
“It is also a testament to our commitment to meet meaningful milestones as we continue our path towards potential regulatory clearance and subsequent commercialization in the US and other regions across the globe."
Microbot shares are moving on heavy trading volume following the company's announcement. According to data from Benzinga Pro, more than 74.7 million shares have already been traded in the session, far exceeding the stock’s 100-day average of less than 96,000 shares.
Related News: What’s Going On With Snowflake Stock?
How To Buy MBOT Stock:
By now you're likely curious about how to participate in the market for Microbot Medical – be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
In the the case of Microbot Medical, which is trading at $1.94 as of publishing time, $100 would buy you 51.55 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.
MBOT Price Action: According to Benzinga Pro, Microbot shares are up 88% at $1.88 at the time of publication Monday.
Image: PublicDomainPictures from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.